Report cover image

Global Group A and C Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 197 Pages
SKU # APRC20277487

Description

Summary

According to APO Research, The global Group A and C Meningococcal Polysaccharide Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Group A and C Meningococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Group A and C Meningococcal Polysaccharide Vaccine include Pfizer, Sanofi Pasteur, AIM Bio, Chengda Biotechnology, GlaxoSmithKline, Cansino Biologics, Sinovac, Lanzhou Institute of Biological Products and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Group A and C Meningococcal Polysaccharide Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Group A and C Meningococcal Polysaccharide Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Group A and C Meningococcal Polysaccharide Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Group A and C Meningococcal Polysaccharide Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Group A and C Meningococcal Polysaccharide Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Group A and C Meningococcal Polysaccharide Vaccine sales, projected growth trends, production technology, application and end-user industry.

Group A and C Meningococcal Polysaccharide Vaccine Segment by Company

Pfizer
Sanofi Pasteur
AIM Bio
Chengda Biotechnology
GlaxoSmithKline
Cansino Biologics
Sinovac
Lanzhou Institute of Biological Products
Royal (Wuxi) Bio-Pharmaceutical
Merck & Co.
Toyouvax
Walvax
Zhifei Biological
Group A and C Meningococcal Polysaccharide Vaccine Segment by Type

Polysaccharide-protein Conjugate Vaccine
Polysaccharide Vaccine
Group A and C Meningococcal Polysaccharide Vaccine Segment by Application

Hospital
Centers for Disease Control and Prevention
Others
Group A and C Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group A and C Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Group A and C Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group A and C Meningococcal Polysaccharide Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Group A and C Meningococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Group A and C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Group A and C Meningococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Group A and C Meningococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Estimates and Forecasts (2020-2031)
1.4 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Estimates and Forecasts (2020-2031)
1.5 Global Group A and C Meningococcal Polysaccharide Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Group A and C Meningococcal Polysaccharide Vaccine Market Dynamics
2.1 Group A and C Meningococcal Polysaccharide Vaccine Industry Trends
2.2 Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers
2.3 Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
2.4 Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints
3 Group A and C Meningococcal Polysaccharide Vaccine Market by Manufacturers
3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (2020-2025)
3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Manufacturers (2020-2025)
3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Sales Price by Manufacturers (2020-2025)
3.4 Global Group A and C Meningococcal Polysaccharide Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers, Product Type & Application
3.7 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Group A and C Meningococcal Polysaccharide Vaccine Players Market Share by Revenue in 2024
3.8.3 2024 Group A and C Meningococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3
4 Group A and C Meningococcal Polysaccharide Vaccine Market by Type
4.1 Group A and C Meningococcal Polysaccharide Vaccine Type Introduction
4.1.1 Polysaccharide-protein Conjugate Vaccine
4.1.2 Polysaccharide Vaccine
4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type
4.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2031)
4.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2031)
4.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type
4.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2020-2031)
4.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2031)
5 Group A and C Meningococcal Polysaccharide Vaccine Market by Application
5.1 Group A and C Meningococcal Polysaccharide Vaccine Application Introduction
5.1.1 Hospital
5.1.2 Centers for Disease Control and Prevention
5.1.3 Others
5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application
5.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2031)
5.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2031)
5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application
5.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2020-2031)
5.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2031)
6 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region
6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2031)
6.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025)
6.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region
7.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region
7.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025)
7.1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2026-2031)
7.1.4 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue (2020-2031)
7.2.2 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue (2020-2031)
7.3.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue (2020-2031)
7.4.2 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Pfizer
8.1.1 Pfizer Comapny Information
8.1.2 Pfizer Business Overview
8.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.1.5 Pfizer Recent Developments
8.2 Sanofi Pasteur
8.2.1 Sanofi Pasteur Comapny Information
8.2.2 Sanofi Pasteur Business Overview
8.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.2.5 Sanofi Pasteur Recent Developments
8.3 AIM Bio
8.3.1 AIM Bio Comapny Information
8.3.2 AIM Bio Business Overview
8.3.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.3.5 AIM Bio Recent Developments
8.4 Chengda Biotechnology
8.4.1 Chengda Biotechnology Comapny Information
8.4.2 Chengda Biotechnology Business Overview
8.4.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.4.5 Chengda Biotechnology Recent Developments
8.5 GlaxoSmithKline
8.5.1 GlaxoSmithKline Comapny Information
8.5.2 GlaxoSmithKline Business Overview
8.5.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.5.5 GlaxoSmithKline Recent Developments
8.6 Cansino Biologics
8.6.1 Cansino Biologics Comapny Information
8.6.2 Cansino Biologics Business Overview
8.6.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.6.5 Cansino Biologics Recent Developments
8.7 Sinovac
8.7.1 Sinovac Comapny Information
8.7.2 Sinovac Business Overview
8.7.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.7.5 Sinovac Recent Developments
8.8 Lanzhou Institute of Biological Products
8.8.1 Lanzhou Institute of Biological Products Comapny Information
8.8.2 Lanzhou Institute of Biological Products Business Overview
8.8.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.8.5 Lanzhou Institute of Biological Products Recent Developments
8.9 Royal (Wuxi) Bio-Pharmaceutical
8.9.1 Royal (Wuxi) Bio-Pharmaceutical Comapny Information
8.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
8.9.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
8.10 Merck & Co.
8.10.1 Merck & Co. Comapny Information
8.10.2 Merck & Co. Business Overview
8.10.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.10.5 Merck & Co. Recent Developments
8.11 Toyouvax
8.11.1 Toyouvax Comapny Information
8.11.2 Toyouvax Business Overview
8.11.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.11.5 Toyouvax Recent Developments
8.12 Walvax
8.12.1 Walvax Comapny Information
8.12.2 Walvax Business Overview
8.12.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.12.5 Walvax Recent Developments
8.13 Zhifei Biological
8.13.1 Zhifei Biological Comapny Information
8.13.2 Zhifei Biological Business Overview
8.13.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
8.13.5 Zhifei Biological Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Group A and C Meningococcal Polysaccharide Vaccine Value Chain Analysis
9.1.1 Group A and C Meningococcal Polysaccharide Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process
9.2 Group A and C Meningococcal Polysaccharide Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
9.2.3 Group A and C Meningococcal Polysaccharide Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.